Summary of Purpose
Nondisabling cerebrovascular events represent the largest group of cerebrovascular disease with a high risk of recurrent stroke. A recent trial indicated that clopidogrel and aspirin treatment reduced the risk of recurrent stroke and was not associated with increased hemorrhage events, compared with aspirin monotherapy. Apixaban, a new oral anticoagulant, is proved to be as effective as traditional anticoagulants...Read More →
The following dates are available for this trial. Trial information last updated on 13 August 2013.
|1 Jan 2014||13 Aug 2013||1 Dec 2015||1 Jul 2016||1 Aug 2013||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
Interventions See All
- Xijing Hospital Lead
- Allocation: Randomized
- Masking: Double Blind (Subject, Caregiver, Investigator)
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
- Xuedong Liu, M.D.
email@example.com +86 029 84775055